Silo Pharma secures license for PTSD treatment SPC-15

Must read

Silo Pharma secures license for PTSD treatment SPC-15 © Reuters.

SARASOTA, FL – Silo Pharma Inc. (NASDAQ:SILO), a biopharmaceutical company specializing in novel therapies for psychiatric and neurological disorders, has exercised an option to exclusively license SPC-15, a drug candidate for the treatment of stress-related affective disorders such as anxiety and PTSD. This decision follows a collaborative pre-clinical research agreement with Columbia University initiated in 2021.

The company is currently finalizing the terms of the license agreement, which will authorize Silo Pharma to develop, manufacture, and commercialize SPC-15 on a global scale.

The agreement is expected to be completed in the first half of 2024. Silo Pharma’s CEO, Eric Weisblum, stated that consistent positive data from pre-clinical studies support the company’s commitment to pursuing exclusive licensing rights for SPC-15.

SPC-15 is an intranasal medication that acts as a serotonin 4 (5-HT4) receptor agonist, offering a different approach compared to the two existing FDA-approved PTSD treatments, which primarily target depressive symptoms. The drug’s unique method of action aims to enhance stress resilience, particularly in high-risk populations.

Silo Pharma has designated the clinical development of SPC-15 as its principal strategic focus for 2024. If successful in clinical trials, SPC-15 could be eligible for the FDA’s 505(b)(2) regulatory pathway, which could expedite the drug approval process.

Apart from SPC-15, Silo Pharma’s pipeline includes SP-26, a time-release implant for chronic pain and fibromyalgia, as well as preclinical compounds SPC-14 and SPU-16, targeting Alzheimer’s disease and multiple sclerosis, respectively. The company’s research efforts are supported by collaborations with Columbia University and the University of Maryland, Baltimore.

The company’s forward-looking statements, as per the press release, caution that actual results may vary due to multiple factors including economic conditions and development challenges. Silo Pharma emphasizes that these statements are based on current expectations and are not guarantees of future performance.

The information in this article is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

More articles

Latest article